Rumored Buzz on ABBV-744 as a potential therapeutic option for aggressive cancers
These side effects have been notably milder when compared with an inhibitor of each bromodomains. A detailed molecular Investigation also exposed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor- "Our study unveiled the essential part in the KLF16/MYC regulatory axis in modulating